Midkine is highly expressed in neuroblastoma tissues.
Standard
Midkine is highly expressed in neuroblastoma tissues. / Fiegel, Henning C; Kaifi, Jussuf; Wachowiak, Robin; Quaas, Alexander; Aridome, Kuniaki; Ichihara-Tanaka, Keiko; Muramatsu, Takashi; Metzger, Roman; Izbicki, Jakob R.; Erttmann, Rudolf; Kluth, Dietrich; Till, Holger.
in: PEDIATR SURG INT, Jahrgang 24, Nr. 12, 12, 2008, S. 1355-1359.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Midkine is highly expressed in neuroblastoma tissues.
AU - Fiegel, Henning C
AU - Kaifi, Jussuf
AU - Wachowiak, Robin
AU - Quaas, Alexander
AU - Aridome, Kuniaki
AU - Ichihara-Tanaka, Keiko
AU - Muramatsu, Takashi
AU - Metzger, Roman
AU - Izbicki, Jakob R.
AU - Erttmann, Rudolf
AU - Kluth, Dietrich
AU - Till, Holger
PY - 2008
Y1 - 2008
N2 - PURPOSE: Neuroblastoma (NBL) is a tumor from neural crest cells, and is the most frequent solid tumor in children. Midkine (MK) is a pleiotropin analogon, which is frequently expressed in neuronal and epithelial tumors and is a marker for a poor clinical outcome. The aims of this study were to assess MK expression in NBL and investigate the correlation with clinical outcome. METHODS: Fifty-six specimens of NBL were stained for MK on a tissue microarray by immunohistochemistry (IHC). Fresh frozen tumor tissues were used for RNA isolation, and RT-PCR analysis for MK-mRNA expression was performed. Survival data, risk factors and disease stages were correlated with MK status assessed by IHC and RT-PCR analysis. RESULTS: MK-mRNA expression was found in the majority of the tumor tissues (75%), whereas MK protein could be detected only in 46% of the NBL by IHC. No correlation of MK status with survival, risk factors or disease stage was observed. CONCLUSION: A majority of NBL express MK-mRNA, whereas not all MK mRNA positive tumors showed also a positive MK IHC staining. The high expression of MK-mRNA expression might present a promising target for new adenovirus-based gene therapeutic approaches for the treatment of NBL.
AB - PURPOSE: Neuroblastoma (NBL) is a tumor from neural crest cells, and is the most frequent solid tumor in children. Midkine (MK) is a pleiotropin analogon, which is frequently expressed in neuronal and epithelial tumors and is a marker for a poor clinical outcome. The aims of this study were to assess MK expression in NBL and investigate the correlation with clinical outcome. METHODS: Fifty-six specimens of NBL were stained for MK on a tissue microarray by immunohistochemistry (IHC). Fresh frozen tumor tissues were used for RNA isolation, and RT-PCR analysis for MK-mRNA expression was performed. Survival data, risk factors and disease stages were correlated with MK status assessed by IHC and RT-PCR analysis. RESULTS: MK-mRNA expression was found in the majority of the tumor tissues (75%), whereas MK protein could be detected only in 46% of the NBL by IHC. No correlation of MK status with survival, risk factors or disease stage was observed. CONCLUSION: A majority of NBL express MK-mRNA, whereas not all MK mRNA positive tumors showed also a positive MK IHC staining. The high expression of MK-mRNA expression might present a promising target for new adenovirus-based gene therapeutic approaches for the treatment of NBL.
M3 - SCORING: Zeitschriftenaufsatz
VL - 24
SP - 1355
EP - 1359
JO - PEDIATR SURG INT
JF - PEDIATR SURG INT
SN - 0179-0358
IS - 12
M1 - 12
ER -
